Mayo Clinic Researchers Combine Common Genetic Variants and Other Factors to Improve Breast Cancer Risk Prediction
Recent large-scale genomic analyses have uncovered dozens of common genetic variants that are associated with breast cancer. Each variant, however, contributes only a tiny amount to a person’s overall risk of developing the disease. A Mayo Clinic-led team of international researchers has now combined 77 of these common genetic variants into a single risk factor that can be used to improve the identification of women with an elevated risk of breast cancer.
Serum thyroglobulin measurement is useful in the follow-up of patients with differentiated follicular cell-derived thyroid carcinoma. After removal of the thyroid gland, thyroglobulin concentrations should be undetectable or very low. The presence of anti-thyroglobulin autoantibodies, which occur in 15 to 30 percent of thyroid cancer patients, could lead to inaccurate quantitation of thyroglobulin. Recently, trypsin digestion of serum proteins has allowed accurate quantification of Tg by mass spectrometry.
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States and in many other developed countries. Women with EC detected at an early stage have a higher likelihood of being cured of their cancer. A recent study by Mayo Clinic researchers, published in Gynecologic Oncology, aims to demonstrate the feasibility of detecting EC by combining minimally invasive specimen collection techniques with sensitive molecular testing.
Refining Individualized Medicine: Study Reduces Time to Deliver Treatment Plan for Melanoma Patients
Evaluating Renal Cell Carcinoma Surveillance Guidelines
- Hot Topic
HPV and p16 Testing in Oropharyngeal Squamous Cell Carcinoma: Indication, Interpretation, and Implication
Renal Cell Carcinoma (RCC) with Rhabdoid Differentiation
Predicting Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis